Skip to content
OpenCapital
Get started

Amgen AMGN Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

Pfizer logo
PfizerPFE
——

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$182.21B+13.3%
Enterprise value$238.97B+9.9%
P/E23.4×-3.7×
P/S4.9×+0.2×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's debt instrument, unamortized discount (premium) and debt issuance costs, net?
Amgen (AMGN) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $1.33B in Q1 2026.
How has Amgen's debt instrument, unamortized discount (premium) and debt issuance costs, net changed year-over-year?
Amgen's debt instrument, unamortized discount (premium) and debt issuance costs, net decreased by 1.2% year-over-year, from $1.35B to $1.33B.
What is the long-term trend for Amgen's debt instrument, unamortized discount (premium) and debt issuance costs, net?
Over 5 years (2020 to 2025), Amgen's debt instrument, unamortized discount (premium) and debt issuance costs, net has grown at a 1.9% compound annual growth rate (CAGR), from $1.19B to $1.31B.